FDA label 7cdcb4d9-3cea-5890-e053-2a91aa0ab509

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
8d8cdd21-2403-4284-bdfc-d56d6e8ab117
SPL ID
7cdcb4d9-3cea-5890-e053-2a91aa0ab509
Version
2
Effective date
2018-12-12
Source export date
2026-11-13
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:52:26

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events occurred with anastrozole tablet use compared to tamoxifen use. Consider risks and benefits. ( 5.1 , 6.1 ) Decreases in bone mineral density may occur. Consider bone mineral density monitoring. ( 5.2 , 6.1 ) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.3 , 6.1 ) 5.1 Ischemic Cardiovascular Events In women with pre-existing ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with anastrozole tablets in the ATAC trial (17% of patients on anastrozole tablets and 10% of patients on tamoxifen). Consider risk and benefits of anastrozole tablets therapy in patients with pre-existing ischemic heart disease [see Adverse Reactions (6.1) ] 5.2 Bone Effects Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole tablets had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline. Consider bone mineral density monitoring in patients treated with anastrozole tablets [see Adverse Reactions (6.1) ]. 5.3 Cholesterol During the ATAC trial, more patients receiving anastrozole tablets were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively) [see Adverse Reactions (6.1) ].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 2 · 7 matching rows.

adverse reactions table

<table width="90%"> <caption>Table 4 &#x2013; Number of Patients with Pre-specified Adverse Reactions in Trials 0030 and 0027</caption> <col width="40%" align="left" valign="top"/> <col width="30%" align="center" valign="top"/> <col width="30%" align="center" valign="top"/> <thead> <tr styleCode="Botrule"> <th/> <th colspan="2">Number (n) and Percentage of Patients</th> </tr> <tr> <th>Adverse Reaction <footnote ID="K1940">A patient may have had more than 1 adverse reaction.</footnote> </th> <th>Anastrozole tablets 1 mg (N=506) n (%) </th> <th>NOLVADEX 20 mg (N=511) n (%) </th> </tr> </thead> <tbody> <tr> <td>Depression</td> <td>23 (5)</td> <td>32 (6)</td> </tr> <tr> <td>Tumor Flare</td> <td>15 (3)</td> <td>18 (4)</td> </tr> <tr> <td>Thromboembolic Disease <footnote ID="t4f2">Includes pulmonary embolus, thrombophlebitis, retinal vein thrombosis.</footnote> </td> <td>18 (4)</td> <td>33 (6)</td> </tr> <tr> <td>Venous <footnoteRef IDREF="t4f2"/> </td> <td>5</td> <td>15</td> </tr> <tr> <td>Coronary and Cerebral <footnote ID="K1991">Includes myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia and cerebral infarct.</footnote> </td> <td>13</td> <td>19</td> </tr> <tr> <td>Gastrointestinal Disturbance</td> <td>170 (34)</td> <td>196 (38)</td> </tr> <tr> <td>Hot Flushes</td> <td>134 (26)</td> <td>118 (23)</td> </tr> <tr> <td>Vaginal Dryness</td> <td>9 (2)</td> <td>3 (1)</td> </tr> <tr> <td>Lethargy</td> <td>6 (1)</td> <td>15 (3)</td> </tr> <tr> <td>Vaginal Bleeding</td> <td>5 (1)</td> <td>11 (2)</td> </tr> <tr> <td>Weight Gain</td> <td>11 (2)</td> <td>8 (2)</td> </tr> </tbody> </table>

adverse reactions table

<table width="90%"> <caption>Table 5 &#x2013; Number (N) and Percentage of Patients with Adverse Reactions in Trials 0004 and 0005</caption> <col width="25%" align="left" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <thead> <tr> <th>Adverse Reaction <footnote ID="K2082">A patient may have had more than one adverse reaction.</footnote> </th> <th>Anastrozole tablets 1 mg (N=262) n (%) </th> <th>Anastrozole tablets 10 mg (N=246) n (%) </th> <th>Megestrol Acetate 160 mg (N=253) n (%) </th> </tr> </thead> <tbody> <tr> <td>Asthenia</td> <td>42 (16)</td> <td>33 (13)</td> <td>47 (19)</td> </tr> <tr> <td>Nausea</td> <td>41 (16)</td> <td>48 (20)</td> <td>28 (11)</td> </tr> <tr> <td>Headache</td> <td>34 (13)</td> <td>44 (18)</td> <td>24 (9)</td> </tr> <tr> <td>Hot Flashes</td> <td>32 (12)</td> <td>29 (11)</td> <td>21 (8)</td> </tr> <tr> <td>Pain</td> <td>28 (11)</td> <td>38 (15)</td> <td>29 (11)</td> </tr> <tr> <td>Back Pain</td> <td>28 (11)</td> <td>26 (11)</td> <td>19 (8)</td> </tr> <tr> <td>Dyspnea</td> <td>24 (9)</td> <td>27 (11)</td> <td>53 (21)</td> </tr> <tr> <td>Vomiting</td> <td>24 (9) </td> <td>26 (11)</td> <td>16 (6)</td> </tr> <tr> <td>Cough Increased</td> <td>22 (8)</td> <td>18 (7)</td> <td>19 (8)</td> </tr> <tr> <td>Diarrhea</td> <td>22 (8)</td> <td>18 (7) </td> <td>7 (3)</td> </tr> <tr> <td>Constipation</td> <td>18 (7)</td> <td>18 (7)</td> <td>21 (8)</td> </tr> <tr> <td>Abdominal Pain</td> <td>18 (7)</td> <td>14 (6)</td> <td>18 (7)</td> </tr> <tr> <td>Anorexia</td> <td>18 (7)</td> <td>19 (8)</td> <td>11 (4)</td> </tr> <tr> <td>Bone Pain</td> <td>17 (6)</td> <td>26 (12)</td> <td>19 (8)</td> </tr> <tr> <td>Pharyngitis</td> <td>16 (6)</td> <td>23 (9)</td> <td>15 (6)</td> </tr> <tr> <td>Dizziness</td> <td>16 (6)</td> <td>12 (5) </td> <td>15 (6)</td> </tr> <tr> <td>Rash</td> <td>15 (6)</td> <td>15 (6)</td> <td>19 (8)</td> </tr> <tr> <td>Dry Mouth</td> <td>15 (6)</td> <td>11 (4)</td> <td>13 (5)</td> </tr> <tr> <td>Peripheral Edema</td> <td>14 (5)</td> <td>21 (9)</td> <td>28 (11)</td> </tr> <tr> <td>Pelvic Pain</td> <td>14 (5)</td> <td>17 (7)</td> <td>13 (5)</td> </tr> <tr> <td>Depression</td> <td>14 (5)</td> <td>6 (2)</td> <td>5 (2)</td> </tr> <tr> <td>Chest Pain</td> <td>13 (5)</td> <td>18 (7)</td> <td>13 (5)</td> </tr> <tr> <td>Paresthesia</td> <td>12 (5)</td> <td>15 (6)</td> <td>9 (4)</td> </tr> <tr> <td>Vaginal Hemorrhage</td> <td>6 (2)</td> <td>4 (2)</td> <td>13 (5)</td> </tr> <tr> <td>Weight Gain</td> <td>4 (2)</td> <td>9 (4)</td> <td>30 (12)</td> </tr> <tr> <td>Sweating</td> <td>4 (2)</td> <td>3 (1)</td> <td>16 (6)</td> </tr> <tr> <td>Increased Appetite</td> <td>0 (0)</td> <td>1 (0)</td> <td>13 (5)</td> </tr> </tbody> </table>

adverse reactions table

<table width="90%"> <caption>Table 6 &#x2013; Number (n) and Percentage of Patients with Pre-specified Adverse Reactions in Trials 0004 and 0005</caption> <col width="25%" align="left" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <col width="25%" align="center" valign="top"/> <thead> <tr> <th valign="bottom">Adverse Reaction Group</th> <th>Anastrozole tablets 1 mg (N=262) n (%) </th> <th>Anastrozole tablets 10 mg (N=246) n (%) </th> <th>Megestrol Acetate 160 mg (N=253) n (%) </th> </tr> </thead> <tbody> <tr> <td>Gastrointestinal Disturbance</td> <td>77 (29)</td> <td>81 (33)</td> <td>54 (21)</td> </tr> <tr> <td>Hot Flushes</td> <td>33 (13)</td> <td>29 (12)</td> <td>35 (14)</td> </tr> <tr> <td>Edema</td> <td>19 (7)</td> <td>28 (11)</td> <td>35 (14)</td> </tr> <tr> <td>Thromboembolic Disease</td> <td>9 (3)</td> <td>4 (2)</td> <td>12 (5)</td> </tr> <tr> <td>Vaginal Dryness</td> <td>5 (2)</td> <td>3 (1)</td> <td>2 (1)</td> </tr> <tr> <td>Weight Gain</td> <td>4 (2)</td> <td>10 (4)</td> <td>30 (12)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.